var _hmt = _hmt || []; (function() { var hm = document.createElement("script"); hm.src = "https://hm.baidu.com/hm.js?d387e539c1f2d34f09a9afbac8032280"; var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s); })();
SAVAUS
Open
Back To Top
Last Updated: Jan 16, 2020 3:54 p.m. EST Real time quote

$ 8.65

0.1998 2.36%
Health Care/Life Sciences 0.01%
Previous Close
$8.45
Advanced Charting
  • $
  • %
  • Vol
Advanced Charting
74.39% vs Avg.
Volume: 3.1M 65 Day Avg. - 4.2M
Open: 8.71
Last: 8.65
8.30 Day Low/High 8.82
Day Range
0.86 52 Week Low/High 10.95

Your Watchlist

Customize MarketWatch

Have Watchlists? Log in to see them here or sign up to get started.

Symbol
Company
Price
Chg/Chg %
No Items in Watchlist

There are currently no items in this Watchlist.

No Saved Watchlists

7073彩票注册Create a list of the investments you want to track.

Uh oh

7073彩票注册Something went wrong while loading Watchlist.

Recently Viewed Tickers

No Recent Tickers

Visit a quote page and your recently viewed tickers will be displayed here.

Key Data

  • Open $8.71
  • Day Range 8.30 - 8.82
  • 52 Week Range 0.86 - 10.95
  • Market Cap $145.5M
  • Shares Outstanding 17.22M
  • Public Float 14.59M
  • Beta 0.81
  • Rev. per Employee n/a
  • P/E Ratio n/a
  • EPS $-0.22
  • Yield n/a
  • Dividend n/a
  • Ex-Dividend Date n/a
  • Short Interest 3.22M 12/31/19
  • % of Float Shorted 22.06%
  • Average Volume 4.17M

Performance

5 Day
  • 9.08%
1 Month
  • 355.25%
3 Month
  • 603.24%
YTD
  • 66.34%
1 Year
  • 633.03%

Recent News

  • MarketWatch
  • WSJ

Cassava Sciences stock price target raised to $12 from $3 at Maxim Group

Cassava's stock rises 33%

Shares of Cassava Sciences Inc. , which is developing treatments for Alzheimer's disease, jumped 33% on heavy volume in premarket trading on Thursday. The company's president and CEO, Remi Barbier, had acquired 100,000 shares of Cassava's stock on Dec. 31. Barbier had also bought an additional 15,198 shares over the course of December. Cassava's stock rallied 24% in December on positive data from a mid-stage trial for PTI-125, one of its experimental Alzheimer's disease drugs. Cassava's stock is up 463% over the last year, while the S&P 500 has gained 28%.

Read full story

Alzheimer’s expert says more clinical trials are needed for controversial Biogen drug

Cassava stock is up on Alzheimer's data

7073彩票注册Shares of Cassava Sciences Inc. jumped 24% on positive data from a mid-stage trial for its experimental Alzheimer's disease drug, PTI-125. The data, which found that the therapy reduced cerebrospinal fluid and plasma biomarkers for Alzheimer's, was released Dec. 5 at the Clinical Trials on Alzheimer's Disease meeting in San Diego. Biogen also released somewhat controversial data about its late-stage Alzheimer's candidate at the conference on Thursday. Cassava stock is up 163% year-to-date. The S&P 500 is up 25%.

Cassava Sciences started at buy with $3 stock price target at Maxim Group

Pain Therapeutics to change name to Cassava Sciences and adopt ticker 'SAVA' fromThursday

Read full story

Pain Therapeutics stock plunges after company slams FDA for refusing to approve drug

Read full story

7073彩票注册 close higher as investors await Trump’s State of the Union speech

UPDATE: Pain Therapeutics shares slide 20% as company charges FDA with basic math errors

Pain Therapeutics shares slide 27% premarket

Pain Therapeutics says FDA made math errors and mistakes in meeting on Remoxy

Pain Therapeutics stock rises on plans to appeal opioid approval decision

Pain Therapeutics stock rises 18% on plans to petition FDA about opioid approval decision

Read full story

U.S. stocks brush off trade jitters to close higher as tech shares gain

UPDATE: Pain Therapeutics shares slide 21% after FDA rejects its non-opioid drug

Pain Therapeutics shares slide 6.6% premarket

Pain Therapeutics says FDA response is 'bizarre conclusion' given toll of opioid abuse problem

Pain Therapeutics has initiated a strategic reorganization to focus on Alzheimer's treatment

Pain Therapeutics says FDA has rejected non-opioid pain treatment

Pain Therapeutics' stock plummets 70% after FDA advisory panel vote disappoints

on The Wall Street Journal

on The Wall Street Journal

on The Wall Street Journal

on The Wall Street Journal

on The Wall Street Journal

on The Wall Street Journal

on The Wall Street Journal

on The Wall Street Journal

on The Wall Street Journal

King Pharma Resubmits Application for Pain Killer

on The Wall Street Journal

Drug-Company Options Active

on The Wall Street Journal

on The Wall Street Journal

New Investment Dartboard Picks

on The Wall Street Journal

William Lyon Homes, Levitt Rise

on The Wall Street Journal

WMS, Pinnacle Prove Good Bets

on The Wall Street Journal

Drug Firms Team Up on Trial Painkiller

on The Wall Street Journal

OxyContin Gets Reformulated

on The Wall Street Journal

Analysts Become Fair Game

on The Wall Street Journal

Stock Underwriting Rebounds

on The Wall Street Journal

Gates Increases Nextel Partners Stake

on The Wall Street Journal

Recent News

  • Other News
  • Press Releases

7073彩票注册Ocugen Stock Is Not for the Faint of Heart

on InvestorPlace.com

Cassava Sciences: Alzheimer's Solution Shows Promise After Positive Phase 2a Trial

on Seeking Alpha

Cassava Sciences: An Investment Opportunity With Some Volatile Periods But A Net Upside

on Seeking Alpha

7073彩票注册Heavy Insider Buying On Cassava Sciences Pushes Up The Stock Price

on Seeking Alpha

FIVE, EXAS among premarket losers

on Seeking Alpha

The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences

on Zacks.com

SRNE, SEEL among premarket gainers

on Seeking Alpha

Multibagger stocks can make most of the bull run, courtesy of strong fundamentals and businesses that can multiply in a short span of time.

on Zacks.com

7073彩票注册Zacks.com featured highlights include: Cassava Sciences, Rubicon Project, Talos Energy, Teekay Tankers and Karyopharm Therapeutics

on Zacks.com

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

on Zacks.com

7073彩票注册PLUG, NIO among premarket gainers

on Seeking Alpha

7073彩票注册PLUG, NIO among premarket gainers

on Seeking Alpha

7073彩票注册Insider Weekends: A Lost Decade Of Insider Buying By Dr. Frost

on Seeking Alpha

Companies in the news are: CMG, SAVA, RCON, IPHA

on Zacks.com

7073彩票注册The Zacks Analyst Blog Highlights: EverQuote, Cassava Sciences, Fulgent Genetics, Teekay Tankers and Cue Biopharma

on Zacks.com

Daily Insider Ratings Round Up 12/31/19

on Seeking Alpha

7073彩票注册WATT, SIG, DRRX and INPX among midday movers

on Seeking Alpha

U.S. stocks rallied to attained fresh all-time highs in 2019, as the momentum continued in 2020. Here are five stocks that are poised to grow.

on Zacks.com

7073彩票注册ACB, RAD among premarket gainers

on Seeking Alpha

Cassava up 25% after hours on CEO stock buys

on Seeking Alpha

Monday 12/23 Insider Buying Report: NLTX, SAVA

7073彩票注册Monday 12/23 Insider Buying Report: NLTX, SAVA

on MarketNewsVideo.com

Cassava Sciences Announces Additional Positive Phase 2a Clinical Data in Alzheimer's Disease at CTAD 2019

on GlobeNewswire

Cassava Sciences Announces Recent Clinical Highlights and Third Quarter 2019 Financial Results

on GlobeNewswire

Cassava Sciences' Clinical Results in Alzheimer's Selected as Late-Breaking News at CTAD 2019

on GlobeNewswire

AM Best Affirms Credit Ratings of Pozavarovalnica Sava d.d.

on BusinessWire - BZX

Cassava Sciences Initiates Phase 2b Clinical Study in Alzheimer's Patients

on GlobeNewswire

Cassava Sciences Reports Positive Phase 2a Clinical Results in Alzheimer's Patients

on GlobeNewswire

Cassava Sciences to Present at H.C. Wainwright's 21st Annual Global Investment Conference

on GlobeNewswire

Cassava Sciences Announces Second Quarter 2019 Financial Results

on GlobeNewswire

Cassava Sciences to Present at Maxim Group's Conference on Alzheimer's Disease

on GlobeNewswire

Cassava Sciences Announces New Website Launch

on GlobeNewswire

Cassava Sciences Reports First Quarter 2019 Financial Results

on GlobeNewswire

Cassava Sciences Completes Patient Enrollment for a Phase 2a Study in Patients with Alzheimer's Disease

on GlobeNewswire

Pain Therapeutics Announces Name Change to Cassava Sciences, Inc.

on GlobeNewswire

Pain Therapeutics Announces Name Change to Cassava Sciences, Inc.

on GlobeNewswire

Pain Therapeutics, Inc. (NASDAQ:PTIE) Files An 8-K Results of Operations and Financial Condition

on Market Exclusive

Pain Therapeutics, Inc. (NASDAQ:PTIE) Files An 8-K Results of Operations and Financial Condition

on Market Exclusive

Pain Therapeutics, Inc. (NASDAQ:PTIE) Files An 8-K Results of Operations and Financial Condition

on Market Exclusive

Pain Therapeutics, Inc. (NASDAQ:PTIE) Files An 8-K Results of Operations and Financial Condition

on Market Exclusive

Pain Therapeutics Reports 2018 Financial Results and Corporate Update

on GlobeNewswire
689彩票邀请码 7072彩票开户 7073彩票注册 963彩票开户 7073彩票网址 7073彩票地址 7073彩票登录 66顺彩票app 8炫彩彩票app 677彩票开户